AR035801A1 - Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos - Google Patents

Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos

Info

Publication number
AR035801A1
AR035801A1 ARP020101149A ARP020101149A AR035801A1 AR 035801 A1 AR035801 A1 AR 035801A1 AR P020101149 A ARP020101149 A AR P020101149A AR P020101149 A ARP020101149 A AR P020101149A AR 035801 A1 AR035801 A1 AR 035801A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
optionally substituted
formula
compound
aryl
Prior art date
Application number
ARP020101149A
Other languages
English (en)
Original Assignee
Telik Inc
Sanwa Kaguku Kenkyusho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc, Sanwa Kaguku Kenkyusho Co Ltd filed Critical Telik Inc
Publication of AR035801A1 publication Critical patent/AR035801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos de acilurea de fórmula (1), (2) o (3) y sus sales farmacéuticamente aceptables, como estereoisómeros únicos o mezclas de estereoisómeros: donde: en la fórmula (1), cada uno de W, X e Y es independientemente CR6R7, N-R7, O o S, con la condición de que al menos uno de W, X e Y sea un átomo de anillo distinto de carbono, y al menos uno de W, X e Y sea un átomo de anillo que sea carbono; en la fórmula (2), W y X son independientemente C-R6 y N e Y es CR6R7, N-R7, O o S, con la condición de que al menos uno de W, X e Y es un átomo de anillo distinto de carbono, y cuando W es C-R6 y X es N, entonces Y es CR6R7; en la fórmula (3), W es CR6R7, N-R7, O o S, y X e Y son independientemente C-R6 y N, con la condición que al menos uno de W, X e Y sea un átomo de anillo distinto de carbono, y cuando X es N e Y es C-R6, entonces W es CR6R7; Z es N o C-R8; cada uno de R1, R2, R6 y R8 es independientemente hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquilo(alquilo inferior), heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, arilo (alquilo inferior) opcionalmente sustituido, halo (alquilo inferior), -CF3, halógeno, nitro, -CN, OR9, -SR9, NR9R10, -NR9(carboxi(alquilo inferior)), -C(=O)R9, -C(=O)OR9, -C(=O)NR9R10, -OC(=O)R9, -SO2R9, -OSO2R9; -SO2NR9R10, -NR9SO2R10 o -NR9C(=O)R10, donde R9 y R10 son independientemente hidrógeno, alquilo inferior opcionalmente sustituido, alquilo inferior-N(C1-2 alquilo)2, alquilo inferior (heterocicloalquilo opcionalmente sustituido), alquenilo, alquinilo, cicloalquilo opcionalmente sustituido, cicloalquilo (alquilo inferior), heterocicloalquilo(alquilo inferior) opcionalmente sustituido, arilo (alquilo inferior), arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilo(alquilo inferior), o R9 y R10 juntos son -(CH2)4-6- opcionalmente interrumpido por un grupo O, S, NH, N-(arilo), N-(arilo(alquilo inferior)), N-(carboxi(alquilo inferior)) o N-(alquilo C1-2 opcionalmente sustituido), R3 y R4 son independientemente hidrógeno, alquilo inferior, alquilo inferior opcionalmente sustituido, arilo opcionalmente sustituido o arilo(alquilo inferior) opcionalmente sustituido o juntos son -(CH2)2-4-; R5 es hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquilo(alquilo inferior), heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, arilo(alquilo inferior) opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilo(alquilo inferior) opcionalmente sustituido, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -SO2R11 o -SO2NR11R12, donde R11 y R12 son independientemente hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquilo(alquilo inferior), arilo, heteroarilo opcionalmente sustituido, heteroarilo(alquilo inferior), o R11 y R12 juntos son -(CH2)4-6-; y cada R7 es hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquilo (alquilo inferior), heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, arilo (alquilo inferior) opcionalmente sustituido, -C(=O)R9, -C(=O)OR9, -C(=O)NR9R10, -SO2R9 o -SO2NR9R10, donde R9 y R10 son independientemente hidrógeno, alquilo inferior opcionalmente sustituido, alquilo inferior-N(C1-2 alquilo)2, alquilo inferior (heterocicloalquilo opcionalmente sustituido), alquenilo, alquinilo, cicloalquilo opcionalmente sustituido, cicloalquilo (alquilo inferior), heterocicloalquilo (alquilo inferior) opcionalmente sustituido, arilo(alquilo inferior), arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilo(alquilo inferior) o R9 y R10 juntos son -(CH2)4-6- opcionalmente interrumpido por un grupo O, S NH, N-(arilo), N-(arilo(alquilo inferior)), N-(carboxi(alquilo inferior)) o N-(alquilo C1-2 opcionalmente sustituido). Los compuestos son antagonistas de la función de proteína-1 quimioatractiva de monocitos (MCP-1) y son útiles en la prevención o tratamiento de enfermedades autoinmunes o inflamatorias crónicas o agudas, especialmente aquellas asociadas con la acumulación aberrante de linfocitos o monocitos tales como artritis, asma, arteriosclerosis, nefropatía diabética, enfermedad intestinal inflamatoria, enfermedad de Crohn, esclerosis múltiple, nefritis, pancreatitis, fibrosis pulmonar, psoriasis, restenosis y rechazo de transplante. También se dan a conocer: composiciones farmacéuticas que comprenden dichos compuestos, el uso de tales compuestos en la preparación de medicamentos, y procesos para la preparación de dichos compuestos. Un proceso para preparar un compuesto o sal de acuerdo con la reivindicación (1), estando dicho proceso caracterizado porque comprende a) poner en contacto un compuesto de la fórmula (4), (5) y (6) donde W, X, Y, Z, R1 y R2 son como se definen en la reivindicación 1 con un compuesto de fórmula R5-N=C=O en condiciones suficientes para producir un compuesto de fórmula (1), (2) o (3) donde R3 y R4 son ambos H; o b) poner en contacto un compuesto de la fórmula (7), (8) y (9), define W, X, Y, Z, R2, R3, R4 y R5 son como se definen en la reivindicación 1 y Q es halógeno, nitro, -CN o OR9 y R9 es como se define en la reivindicación (1) con un compuesto del la fórmula: R1-H en condiciones suficientes para producir un compuesto de fórmula (1), (2) o (3): c) poner en contacto un compuesto de fórmula (4), (5) y (6), donde W, X, Y, Z, R1 y R2 son como se definen en la reivindicación 1, con un reactivo de haloformilación y un compuesto de fórmula (10) en condiciones suficientes para producir un compuesto de fórmula (1), (2) o (3), donde R4 es H; o d) elaborar sustituyentes de un compuesto de fórmula (1), (2) o (3) en una manera conocida de por sí; o e) hacer reaccionar la base libre de un compuesto de fórmula (1), (2) o (3) con un ácido para obtener una sal de adición farmacéuticamente aceptable, o f) hacer reaccionar una sal de adición ácida de un compuesto de fórmula (1), (2) o (3) con una base para formar la correspondiente base libre; o g) convertir una sal de un compuesto de fórmulas (1), (2) y (3) en otra sal farmacéuticamente aceptable de un compuesto de fórmulas (1), (2) o (3); o h) resolver una mezcla racémica de cualquier proporción de un compuesto de fórmula (1), (2) o (3) para producir un esteroisómero del mismo.
ARP020101149A 2001-04-03 2002-03-27 Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos AR035801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28127401P 2001-04-03 2001-04-03

Publications (1)

Publication Number Publication Date
AR035801A1 true AR035801A1 (es) 2004-07-14

Family

ID=23076618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101149A AR035801A1 (es) 2001-04-03 2002-03-27 Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos

Country Status (16)

Country Link
US (2) US6677365B2 (es)
EP (1) EP1383757B1 (es)
JP (1) JP2004525951A (es)
KR (1) KR20040018346A (es)
CN (1) CN1260222C (es)
AR (1) AR035801A1 (es)
AT (1) ATE340789T1 (es)
AU (1) AU2002307014B2 (es)
BR (1) BR0208667A (es)
CA (1) CA2442776A1 (es)
DE (1) DE60214996T2 (es)
ES (1) ES2272761T3 (es)
HK (1) HK1060727A1 (es)
MX (1) MXPA03008962A (es)
TW (1) TWI236474B (es)
WO (1) WO2002081463A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7223796B2 (en) 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP2007523929A (ja) * 2004-02-26 2007-08-23 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ベンズイミダゾリル誘導体
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
CA2606174A1 (en) * 2005-04-18 2006-10-26 Saeed R. Khan Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2009081892A1 (ja) * 2007-12-25 2009-07-02 Kissei Pharmaceutical Co., Ltd. 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
CL2009000250A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
WO2010039538A2 (en) 2008-09-23 2010-04-08 Georgetown University Flavivirus inhibitors and methods for their use
EP2344481B9 (en) 2008-09-23 2014-12-31 Georgetown University Viral and fungal inhibitors
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
HUE042335T2 (hu) 2014-10-14 2019-06-28 Vitae Pharmaceuticals Inc ROR-gamma dihidropirrolopiridin inhibitorai
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250611A (es) 1968-02-03 1971-10-20
IE32700B1 (en) 1968-02-03 1973-10-31 Beecham Group Ltd Penicillins
DE2131034A1 (de) 1971-06-23 1973-01-11 Hoechst Ag Acylharnstoffe und verfahren zu ihrer herstellung
DE2652004C3 (de) 1976-11-15 1979-09-13 Basf Ag, 6700 Ludwigshafen l-Acyl-2-arylamino-2-imidazoline, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2672888B1 (fr) 1991-02-14 1994-02-04 Fabre Medicament Pierre Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
JPH09255572A (ja) 1996-03-26 1997-09-30 Takeda Chem Ind Ltd ケモカイン受容体拮抗剤
EP0914319B1 (en) 1996-05-20 2001-11-21 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU3633997A (en) 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
AU2720199A (en) 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
EP1101759A4 (en) 1998-07-31 2001-12-12 Nippon Soda Co PHENYLAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICATIONS FOR HYPERLIPEMY
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6316449B1 (en) 1999-07-08 2001-11-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
US6777413B2 (en) 2000-02-01 2004-08-17 Millennium Pharmaceuticals, Inc. 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives

Also Published As

Publication number Publication date
BR0208667A (pt) 2004-08-03
US20030092728A1 (en) 2003-05-15
US6998407B2 (en) 2006-02-14
ES2272761T3 (es) 2007-05-01
AU2002307014B2 (en) 2007-04-26
TWI236474B (en) 2005-07-21
MXPA03008962A (es) 2004-10-15
EP1383757B1 (en) 2006-09-27
ATE340789T1 (de) 2006-10-15
CN1260222C (zh) 2006-06-21
DE60214996T2 (de) 2007-05-24
WO2002081463A1 (en) 2002-10-17
KR20040018346A (ko) 2004-03-03
EP1383757A1 (en) 2004-01-28
CN1524078A (zh) 2004-08-25
US20040127513A1 (en) 2004-07-01
CA2442776A1 (en) 2002-10-17
JP2004525951A (ja) 2004-08-26
DE60214996D1 (de) 2006-11-09
HK1060727A1 (en) 2004-08-20
US6677365B2 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
AR035801A1 (es) Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
AR035743A1 (es) Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos y procesos para la preparacion de dichos compuestos.
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
IL176247A0 (en) Cyclopropane compounds and pharmaceutical use thereof
US3318952A (en) Dibenzylsulfamides
KR20190140910A (ko) 아폽토시스-유도제
CS251760B2 (en) Method of benzazepines and benzodiazepines production
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
RU2004112780A (ru) Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения
PE20030137A1 (es) Derivados antimicrobianos de quinolona
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
NO933100L (no) Eksitatoriske aminosyre reseptorantagonister
RS20060143A (en) Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
MX2010005753A (es) Derivados de isoxazolo-pirazina.
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
DE50010886D1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
BR0215017A (pt) Lactamas como antagonistas da taquiquinina
HUP0201356A2 (hu) Ösztrogén agonisták/antagonisták alkalmazása depresszió kezelésére vagy a kognitív funkció romlásának megelőzésére alkalmas gyógyászati készítmény előállítására
HUP9800051A2 (hu) 1-Aril-2-acil-amino-etán-vegyületek, alkalmazásuk neurokinin-antagonista gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
US3351584A (en) Nu-propargyl sulfamides
ES2167617T3 (es) Derivados de 1-bencenosulfonilpirrolidina como antagonistas del receptor de la bradiquinina.
HUP9801089A2 (hu) Benzolszulfonamidszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FA Abandonment or withdrawal